MarketPulse
D

$DNTH

5 articles found
3 positive
0 negative
2 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

LBL-047 Advances to Clinical Testing for Autoimmune Diseases as Dianthus Raises $719M

Nanjing Leads Biolabs and Dianthus Therapeutics advance LBL-047, a bifunctional fusion protein, into Phase 1 trials for three autoimmune conditions with $719M in funding.
DNTHclinical developmentautoimmune disease
The Motley FoolThe Motley Fool··Cory Renauer

Dianthus CFO Sells $739K in Stock as Biotech Eyes Phase 3 Success

Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares for $739,000 on April 9, 2026, reducing direct holdings to zero while retaining substantial options.
DNTHmonoclonal antibodybiotech
The Motley FoolThe Motley Fool··Pamela Kock

Dianthus CFO Cashes Out $9.5M in Stock After 402% Rally

Dianthus CFO Ryan Savitz sold $9.5M in stock, liquidating all direct holdings while retaining options, following the company's exceptional 402% year-over-year rally.
DNTHmonoclonal antibodybiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dianthus Therapeutics Raises $625M in Upsized IPO Offering to Fund Pipeline Expansion

Dianthus Therapeutics prices $625M upsized offering at $81/share to fund drug development and commercial readiness. Closing expected March 12, 2026.
DNTHbiotechclinical-stage
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dianthus to Unveil Phase 3 CIDP Trial Data as Claseprubart Nears Potential Breakthrough

Dianthus Therapeutics will present interim responder analysis from Phase 3 CAPTIVATE trial of claseprubart for CIDP treatment on March 9, 2026.
DNTHclinical-stage biotechPhase 3 trial